Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

devatis pty ltd - amoxicillin trihydrate, quantity: 91.823 mg/ml; potassium clavulanate, quantity: 13.58 mg/ml - suspension, powder for - excipient ingredients: xanthan gum; hypromellose; silicon dioxide; saccharin sodium; methyl hydroxybenzoate; succinic acid; colloidal anhydrous silica; flavour - amoklavin duo 400/57 (amoxicillin and clavulanic acid) oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology):,skin and skin structure infections,urinary tract infections (complicated and uncomplicated),upper respiratory tract infections including sinusitis and otitis media,lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoklavin duo 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoklavin duo 400/57, should not require the addition of another antibiotic due to the amoxicillin content of amoklavin duo 400/57.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

devatis pty ltd - amoxicillin trihydrate, quantity: 91.823 mg/ml; potassium clavulanate, quantity: 13.58 mg/ml - suspension, powder for - excipient ingredients: saccharin sodium; xanthan gum; methyl hydroxybenzoate; succinic acid; colloidal anhydrous silica; silicon dioxide; hypromellose; flavour - deva-amoxyclav 400/57 (amoxicillin and clavulanic acid) oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology):,skin and skin structure infections,urinary tract infections (complicated and uncomplicated),upper respiratory tract infections including sinusitis and otitis media,lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to deva-amoxyclav 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to deva-amoxyclav 400/57, should not require the addition of another antibiotic due to the amoxicillin content of deva-amoxyclav 400/57.

Irska - angleščina - HPRA (Health Products Regulatory Authority)

vetoquinol ireland limited - marbofloxacin - powder and solvent for solution for injection - 1 percent weight/volume - marbofloxacin - cats, dogs - antibacterial

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - azithromycin dihydrate, quantity: 524.1 mg (equivalent: azithromycin, qty 500 mg) - solution, powder for - excipient ingredients: sodium hydroxide; citric acid monohydrate - community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae,staphylococcus aureus and streptococcus pneumoniae

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - azithromycin, quantity: 500 mg (equivalent: azithromycin monohydrate, qty 512.029 mg) - injection, powder for - excipient ingredients: sodium hydroxide; citric acid - community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - azithromycin, quantity: 500 mg - injection, powder for - excipient ingredients: sodium hydroxide; citric acid monohydrate - community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - azithromycin dihydrate, quantity: 524.1 mg (equivalent: azithromycin, qty 500 mg) - injection, powder for - excipient ingredients: citric acid; sodium hydroxide - community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus and streptococcus pneumoniae.

Avstralija - angleščina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - florfenicol - parenteral liquid/solution/suspension - florfenicol antibiotic active 300.0 mg/ml - antibiotic & related - cattle | pigs | beef | boar | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | gilt | hei - actinobacillus pleuropneumoniae (haemoph | bacterial infection | bovine respiratory disease | footrot - dichelobacter nodosus | fusobacterium necrophorum | haemophilus spp. | mycoplasma spp. | pasteurella multocida | pink-eye | streptococcus suis | swine dysentery | amoxycillin sensitive bacteria | associated with viral disease | fowl cholera | gram negative organisms | gram positive organisms | haemophilus agni | haemophilus bovis | haemophilus parainfluenzae | haemophilus parasuis | haemophilus pleuropneumoniae | haemophilus somnus | haemophilus suis | post parturient bacterial infe | primary bacterial infection | shipping fever | sulfadiazine sensitive bacteri | trimethoprim sensitive bacteri | tylosin sensitive bacteria

Avstralija - angleščina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - cephalexin as the sodium salt - parenteral liquid/solution/suspension - cephalexin as the sodium salt antibiotic active 180.0 mg/ml - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - corynebacterium spp. | escherichia coli (e. coli) | micrococcus spp. | moraxella spp. | pasteurella multocida | proteus spp. | staphylococci | streptococci | bacterial canker | fowl cholera | including b-lactamase producin

Kanada - angleščina - Health Canada

glaxosmithkline inc - amoxicillin (amoxicillin trihydrate); clavulanic acid (clavulanate potassium) - powder for suspension - 125mg; 31.25mg - amoxicillin (amoxicillin trihydrate) 125mg; clavulanic acid (clavulanate potassium) 31.25mg - aminopenicillins